[et_pb_section fb_built=”1″ _builder_version=”4.16″ custom_css_main_element=”padding:0;” global_colors_info=”{}”][et_pb_row _builder_version=”4.25.1″ background_enable_color=”off” background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_image src=”https:\/\/ariannafoundation.org\/web\/wp-content\/uploads\/2017\/12\/pubblicazioni_Arianna-1.jpg” align_tablet=”center” align_phone=”center” align_last_edited=”on|desktop” admin_label=”TESTATA” _builder_version=”4.16″ custom_css_main_element=”margin-bottom: 0px !important;” global_colors_info=”{}”][\/et_pb_image][et_pb_image src=”https:\/\/ariannafoundation.org\/web\/wp-content\/uploads\/2018\/06\/Fondazione_Arianna_pubblicazioni-1.png” align_tablet=”center” align_phone=”center” align_last_edited=”on|desktop” admin_label=”TITOLO” module_class=”headerINT” _builder_version=”4.25.1″ background_color=”#80130b” custom_padding=”8px|8px|8px|8px|false|false” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.16″ text_font_size=”16px” header_3_text_align=”left” custom_padding=”15px|15px|15px|15px” animation_style=”fold” border_radii=”on|6px|6px|6px|6px” border_width_all=”2px” border_color_all=”#ffffff” box_shadow_style=”preset3″ box_shadow_horizontal=”2px” box_shadow_vertical=”10px” box_shadow_color=”rgba(214,214,214,0.3)” global_colors_info=”{}”]<\/p>\n
L\u2019attivit\u00e0 scientifica promossa da Fondazione Arianna ha portato alla pubblicazione dei lavori su importanti riviste internazionali.<\/strong> [\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.16″ global_colors_info=”{}”]<\/p>\n [\/et_pb_text][et_pb_divider color=”#80130b” divider_style=”inset” _builder_version=”4.16″ module_alignment=”left” height=”5px” global_colors_info=”{}”][\/et_pb_divider][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_3,1_3,1_3″ _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”1_3″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_image src=”https:\/\/ariannafoundation.org\/web\/wp-content\/uploads\/2018\/06\/The-Italian-Register-cover.jpg” url=”https:\/\/ariannafoundation.org\/web\/wp-content\/uploads\/2018\/06\/The-Italian-Register_L.pdf” url_new_window=”on” align_tablet=”center” align_phone=”center” align_last_edited=”on|desktop” _builder_version=”4.16″ global_colors_info=”{}”][\/et_pb_image][et_pb_text _builder_version=”4.16″ custom_padding=”5px|5px|5px|5px” border_width_left=”2px” border_color_left=”#80130b” global_colors_info=”{}”]<\/p>\n START-Register. The Italian START-Register on Anticoagulation with Focus on Atrial Fibrillation.<\/strong> [\/et_pb_text][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_image src=”https:\/\/ariannafoundation.org\/web\/wp-content\/uploads\/2018\/06\/VitaminaK_cover.jpg” url=”https:\/\/ariannafoundation.org\/web\/wp-content\/uploads\/2018\/06\/VitaminaK_L.pdf” url_new_window=”on” align_tablet=”center” align_phone=”center” align_last_edited=”on|desktop” _builder_version=”4.16″ global_colors_info=”{}”][\/et_pb_image][et_pb_text _builder_version=”4.16″ custom_padding=”5px|5px|5px|5px” border_width_left=”2px” border_color_left=”#80130b” global_colors_info=”{}”]<\/p>\n Vitamin K Antagonist Therapy: Changes in the Treated Populations and in Management Results in Italian Anticoagulation Clinics Compared with those recorded 20 years ago.<\/strong> \u00a0<\/span><\/p>\n [\/et_pb_text][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_image src=”https:\/\/ariannafoundation.org\/web\/wp-content\/uploads\/2018\/06\/Prevalence_cover.jpg” url=”https:\/\/ariannafoundation.org\/web\/wp-content\/uploads\/2018\/06\/Prevalence_L.pdf” url_new_window=”on” align_tablet=”center” align_phone=”center” align_last_edited=”on|desktop” _builder_version=”4.16″ global_colors_info=”{}”][\/et_pb_image][et_pb_text _builder_version=”4.16″ custom_padding=”5px|5px|5px|5px” border_width_left=”2px” border_color_left=”#80130b” global_colors_info=”{}”]<\/p>\n Prevalence and predictors of dual antiplatelet therapy prolongation beyond one year in patients with acute coronary syndrome. [\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.25.1″ hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n [\/et_pb_text][et_pb_divider color=”#80130b” divider_style=”inset” _builder_version=”4.16″ module_alignment=”left” height=”5px” global_colors_info=”{}”][\/et_pb_divider][et_pb_text _builder_version=”4.25.1″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n Menichelli D, Gazzaniga G,\u00a0Antonucci E, Palareti G, Poli D, Pignatelli P,\u00a0Pastori D; START2 Register Investigators<\/i><\/b>. Effectiveness of direct oral anticoagulants for all-cause mortality and cardiovascular events in overweight and obese patients with atrial fibrillation: Insight from the nationwide START registry<\/span><\/i>.\u00a0 <\/span><\/i>Eur J Clin Invest. 2025<\/b><\/a><\/p>\n Menichelli D, Gazzaniga G, Poli D, Palareti G, Antonucci E, Pani A, Pignatelli P, Pastori D; START2 Register Investigators<\/i><\/b>. Real-world use of direct oral anticoagulants in atrial fibrillation patients with moderate\/severe chronic kidney disease: a propensity score matched analysis from the START registry.<\/span><\/i> Clin Res Cardiol. 2025<\/b><\/a><\/p>\n Pengo V, Sarti L, Poli D, Sivera P, Barcellona D, Prisco D, Pizzini AM, Vercillo G, Antonucci E, Palareti G; Start2 Antiphospholipid Registry collaborators<\/i><\/b>.\u00a0 Application of ACR\/EULAR Classification Criteria in Real Life: Thrombotic Patients Positive for Lupus Anticoagulant Only. <\/span><\/i>Semin Thromb Hemost. 2025<\/i><\/strong><\/a><\/p>\n Menichelli D, Antonucci E, Poli D, Baratta F, Sciacqua A, Armentaro G, Gazzaniga G, Moscucci F, Palareti G, Farcomeni A, Ettorre E, Desideri G, Violi F, Pignatelli P, Pastori D; START2 Register Investigators.<\/i><\/b> Frailty elements, direct oral anticoagulants and mortality risk in atrial fibrillation patients aged<\/span><\/i>\u2009<\/span><\/i>\u2265<\/span><\/i>\u2009<\/span><\/i>80 or<\/span><\/i>\u2009<\/span><\/i>\u2265<\/span><\/i>\u2009<\/span><\/i>90 years from the nationwide Italian START registry: a propensity score matching analysis. <\/span><\/i>Geroscience. 2025<\/b><\/a><\/p>\n Stefania Cavazza, Gualtiero Palareti<\/i><\/b>\u00a0 Still unmet problems with low molecular weight heparin prophylaxis of venous thromboembolism. An Italian survey. BTVB 2025<\/a><\/strong><\/span><\/i><\/p>\n Menichelli D, Antonucci E, Gazzaniga G, Poli D, Armentaro G, di Carlo G, Marcucci R, Calabr\u00f2 P, Cesaro A, Palareti G, Sciacqua A, Pignatelli P, Pastori D; START 2 Collaborators* <\/i><\/b>Atrial Fibrillation, Heart Failure Phenotypes, and Mortality Risk in the Nationwide START Registry: A Propensity Score Matching Analysis. <\/span><\/i>J Am Heart Assoc. 2025<\/b><\/a><\/p>\n Aiello A, Sarti L, Sandri G, Poli D, Sivera P, Barcellona D, Prisco D, Pizzini AM, Vercillo G, Antonucci E, Palareti G, Pengo V; Start2 Antiphospholipid Registry collaborators. <\/i><\/b>Impact of the 2023 ACR\/EULAR Classification Criteria on START2 Antiphospholipid Registry.<\/span><\/i> Int J Lab Hematol. 2025<\/i><\/b><\/a><\/p>\n Palareti G, Legnani C, Testa S, Paoletti O, Cini M, Antonucci E, Pengo V, Poli D, Ageno W, Prandoni P, Prisco D, Tosetto A; MAS Working Group. <\/i><\/b>Can the Charlson comorbidity index help to guide DOAC dosing in patients with atrial fibrillation and improve the efficacy and safety of treatment? A subanalysis of the MAS study.<\/span><\/i> Curr Probl Cardiol. 2025<\/i><\/b><\/a><\/p>\n De Sio V, Gragnano F, Capolongo A, Guarnaccia N, Maddaluna P, Acerbo V, Galli M, Berteotti M, Sperlongano S, Cesaro A, Moscarella E, Pelliccia F, Patti G, Antonucci E, Cirillo P, Pignatelli P, Palareti G, Pengo V, Gresele P, Marcucci R, Calabr\u00f2 P. <\/i><\/b>Eligibility for and practical implications of Semaglutide in overweight and obese patients with acute coronary syndrome<\/span><\/i>. <\/b>Int J Cardiol\u00a0 2025<\/b> <\/a><\/p>\n Cirillo P, Di Serafino L, Scalamogna M, De Rosa G, Calabr\u00f2 P, Antonucci E, Gresele P, Palareti G, Patti G, Pengo V, Pignatelli P, Marcucci R<\/i><\/b>. ACEF vs PARIS score in Predicting Cardiovascular Events in Patients With Acute Coronary Syndrome: Insights From the START ANTIPLATELET\u00a0<\/i>Registry. Angiology. 2024<\/a><\/b><\/span><\/p>\n Cirillo P, Di Serafino L, Scalamogna M, De Rosa G, Calabr\u00f2 P, Antonucci E, Gresele P, Palareti G, Patti G, Pengo V, Pignatelli P, Marcucci R<\/i><\/b>. ACEF vs PARIS score in Predicting Cardiovascular Events in Patients With Acute Coronary Syndrome: Insights From the START ANTIPLATELET\u00a0<\/i>Registry. Angiology. 2024<\/a><\/b><\/span><\/p>\n Palareti G, Testa S, Legnani C, Paoletti O, Cini M, Antonucci E, Pengo V, Poli D, Ageno W, Prandoni P, Prisco D, Tosetto A; MAS Study group<\/i><\/b>. The use of reduced DOAC doses in atrial fibrillation patients does not always lead to good anticoagulation levels and avoid adverse events.\u00a0<\/i>Int J Cardiol. 2024<\/b><\/span><\/a><\/p>\n Parisi R, Antonucci E, Bucherini E, Chistolini A, Di Giorgio A, Di giulio R, Mastroiacovo D, Marzolo M, Pancani R, Pastori D, Podda GM, Sivera P, Poli D, Palareti G.\u00a0<\/i><\/b>Venous Thromboembolism: A Chronic Disease.\u00a0<\/i>Journ Clin Med Case Studies 2024<\/i><\/b><\/p>\n Gresele P, Guglielmini G, Del Pinto M, Calabr\u00f2 P, Pignatelli P, Patti G, Pengo V, Antonucci E, Cirillo P, Fierro T, Palareti G, Marcucci R; START Antiplatelet Registry Group.\u00a0<\/i><\/b>Low platelet count at admission has an adverse impact on outcome in patients with acute coronary syndromes: from the START Antiplatelet registry<\/i>.<\/i><\/b>Sci Rep. 2024<\/strong><\/span><\/a><\/p>\n Palareti G, Legnani C, Tosetto A, Poli D, Testa S, Ageno W, Pengo V, Cosmi B, Prandoni P.\u00a0<\/i><\/b>D-dimer and risk of venous thromboembolism recurrence: Comparison of two studies with similar designs but different laboratory and clinical results.\u00a0<\/i>Thromb Res 2024<\/b><\/span><\/a><\/p>\n Bernardini A, Bindini L, Antonucci E, Berteotti M, Giusti B, Testa S, Palareti G, Poli D, Frasconi P, Marcucci R.\u00a0<\/i><\/b>Machine learning approach for prediction of outcomes in anticoagulated patients with atrial fibrillation.<\/i>\u00a0Int J Cardiol. 2024<\/b><\/span><\/a><\/p>\n Palareti G, Testa S, Legnani C, Dellanoce C, Cini M, Paoletti O, Ciampa A, Antonucci E, Poli D, Morandini R, Tala M, Chiarugi P, Santoro RC, Iannone AM, De Candia E, Pignatelli P, Faioni EM, Chistolini A, Esteban MDP, Marietta M, Tripodi A, Tosetto A<\/i><\/b>, for the MAS Study Group. More Early Bleeds Associated With High Baseline Direct Oral Anticoagulant Levels In Atrial Fibrillation: The MAS Study.\u00a0<\/i>Blood Adv. 2024<\/b><\/span><\/a><\/p>\n Poli D, Antonucci E, Ageno W, Berteotti M, Falanga A, Pengo V, Chiarugi P, Cosmi B, Paparo C, Chistolini A, Insana A, Lione D, Malcangi G, Martini G, Masciocco L, Pedrini S, Bucherini E, Pastori D, Pignatelli P, Toma A, Testa S, Palareti G, Start AF Study Group.<\/i><\/b>Inappropriate Underdosing of Direct Oral Anticoagulants in Atrial Fibrillation Patients: Results from the START2-AF Registry.\u00a0<\/i>J Clin Med. 2024<\/b><\/span><\/a><\/p>\n Palareti G, Antonucci E, Bucherini E, Caronna A, Chistolini A, Di Giorgio A, Di Giulio R, Falanga A, Fregoni V, Garzia M, Mastroiacovo D, Marzolo M, Pancani R, Pastori D, Podda GM, Rigoni AM, Ria L, Sivera P, Testa S, Vison\u00e0 A, Parisi R, Poli D, On Behalf Of The Start Post Vte Investigators.\u00a0<\/i><\/b>Long-Term Outcomes in Two-Year Follow-Up after Primary Treatment in Patients with a Prior Venous Thromboembolic Event: A Prospective, Observational, Real-Life Study.<\/i>J Clin Med. 2024<\/b><\/span><\/a><\/p>\n Pengo V, Sarti L, Antonucci E, Bison E, Pontara E, Cattini MG, Denas G, Poli D, Palareti G.\u00a0<\/i><\/b>Patients with antiphospholipid syndrome and a first venous or arterial thrombotic event: clinical characteristics, antibody profiles and estimate of the risk of recurrence.\u00a0<\/i>Clin Chem Lab Med. 2024<\/b><\/span><\/a><\/p>\n Testa S, Palareti G, Legnani C, Dellanoce C, Cini M, Paoletti O, Ciampa A, Antonucci E, Poli D, Morandini R, Tala M, Chiarugi P, Santoro RC, Iannone AM, De Candia E, Pignatelli P, Faioni EM, Chistolini A, Esteban MDP, Marietta M, Tripodi A, Tosetto A<\/i><\/b>.Thrombotic events associated with low baseline direct oral anticoagulant levels in atrial fibrillation: the MAS study<\/i>.\u00a0<\/i><\/b>Blood Adv. 2024<\/span><\/a><\/strong><\/p>\n Rostagno C, Rubbieri G, Zeppa M, Cartei A, Ceccofiglio A, Mannarino GM, Palareti G, Grandone E.<\/i><\/b>Management and 1-Year Outcome in Elderly Patients with Hip Fracture Surgery Receiving Anticoagulation (Warfarin or DOAc) or P2Y12 Antiplatelet Agents.\u00a0<\/i>J Clin Med. 2023<\/b><\/span><\/a><\/p>\n \u00a0<\/b>Menichelli D, Poli D, Antonucci E, Palareti G, Pignatelli P, Pastori D.<\/i><\/b>\u00a0Renin-angiotensin-aldosterone system inhibitors and mortality risk in elderly patients with atrial fibrillation. Insights from the nationwide START registry.\u00a0<\/i>Eur J Intern Med. 202<\/b>3<\/span><\/a><\/p>\n Pengo V \u00a0Sarti L, Antonucci E, Di Agostino S, Bison E, Denas G, Poli D, Meroni PL Gerli R, Radice A, Palareti G.<\/i><\/b>\u00a0Descriptive analysis of patients positive for anti-phospholipid antibodies included in two Italian registries.\u00a0<\/i>BTVB 2023<\/b><\/span><\/a><\/p>\n Menichelli D, Antonucci E, Pignatelli P, Violi F, Palareti G, Pastori D; START2 Register Investigators.<\/i><\/b>\u00a0Statins under-treatment and mortality in patients with atrial fibrillation. Insights from the nationwide START registry.\u00a0<\/i>Nutr Metab Cardiovasc Dis. 2023<\/b><\/span><\/a><\/p>\n Guarascio M, Bert\u00f9 L, Donadini MP, Antonucci E, Palareti G, Ageno W<\/i><\/b>. DOACs use in extreme body-weighted patients: results from the prospective START-register.<\/i>\u00a0Intern Emerg Med. 2023<\/b><\/span><\/a><\/p>\n Poli D, Ageno W, Antonucci E, Bradamante S Bucherini E, Chiarugi P, Chistolini A, Cosmi B , Falanga A, Insana A, Lione D, Lombardi MR, Malcangi G, Marcucci R,\u00a0\u00a0 Martini G, Masciocco L, Paparo C, Pastori D, Pedrini S, Pengo V, Pignatelli P, Toma A testa S, Palareti G<\/i><\/b>.\u00a0Management of anticoagulation in atrial fibrillation patients in Italy: insight from the Atrial Fibrillation-Survey on Anticoagulated Patients Register (AF-START).\u00a0<\/i>BTVB 2023<\/b><\/span><\/a><\/p>\n Grandone E, Antonucci E, Colaizzo D, De Laurenzo A, Cosmi B, Cini M, Legnani C, Testa S, Margaglione M, Palareti G<\/i><\/b>. Venous thromboembolism in women of childbearing age: insights from the START registry.<\/i>\u00a0Thromb Haemost. 2023<\/b><\/span><\/a><\/p>\n Ageno W, Antonucci E, Poli D, Bucherini E, Chistolini A, Fregoni V, Lerede T, Pancani R, Pedrini S, Pieralli F, Pignatelli P, Pizzini AM, Podda GM, Potere N, Sarti L, Testa S, Vison\u00e0 A, Palareti G; START 2 Registry VTE study group<\/i><\/b>.\u00a0 Venous thromboembolism secondary to hospitalization for COVID-19: patient management and long-term outcomes.\u00a0<\/i>Res Pract Thromb Haemost. 2023<\/b><\/span><\/a><\/p>\n Palareti G, Legnani C, Poli D, Ageno W, Pengo V, Testa S, Tosetto A, Prandoni P; NEUROFARBA<\/i><\/b>,\u00a0University of Florence, Italy. COVID-19 pandemic affects the ability of negative D-dimer to identify venous thromboembolism patients at low risk of recurrence: insights from the Apidulcis study.\u00a0<\/i>Haematologica 2023<\/b><\/span><\/a><\/p>\n
\nInoltre, numerosi contributi sui dati analizzati sono stati selezionati come poster o come comunicazioni orali ai pi\u00f9 importanti congressi nazionali e internazionali sull\u2019anticoagulazione.<\/span><\/p>\nCONSULTA E SCARICA I NOSTRI ARTICOLI<\/span><\/h3>\n
\nAntonucci E, Poli D, Tosetto A, Pengo V, Tripodi A, Magrini N, Marongiu F, Palareti G.
\nPLosOne 2015<\/span><\/p>\n
\n<\/span>Palareti G, Antonucci E, Migliaccio L, Erba N, Marongiu F, Pengo V, Poli D, Testa S, Tosetto A, Tripodi A, Moia M; on behalf of the centres participating in the FCSA-START-Register (The ISCOAT 2016 study)
\n<\/span>Intern and Emerg Med, 2017<\/p>\n
\n<\/span><\/strong>Patti G, et al. Calabr\u00f2 P, Cirillo P, Gresele P, Palareti G, Pengo V, Pignatelli P, Ricottini E, Marcucci R.
\nPLoS One. 2017<\/span><\/p>\nARTICOLI PUBBLICATI<\/span><\/h3>\n